NRG-GY037

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

Principal Investigator

Jyoti Mayadev, MD

Co-Principal Investigator(s)

Dmitriy Zamarin, MD

Status

Disease Site

Gynecologic [GY] Cervix

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine whether induction IO and chemotherapy prior to CRT+IO improves progression-free survival (PFS) compared to CRT+IO alone.

 

Patient Population

Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma.

Target Accrual

336